This course has expired. View available courses.
Expired
Expanding the horizon for Refractory and Relapsing Chronic Lymphocytic Leukaemia and Follicular Lymphoma – Certificate of Completion
Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma has undergone significant evolution over the last decade with the advent of rituximab. Since then, a new class of targeted therapies has been developed which offers the possibility of a paradigm shift in this disease, with greater effectiveness in prolongation of progression-free survival compared to standard therapies.
DURATION
1.5 hrs
PROFESSION
Specialist
# OF CREDITS
1.5
ACCREDITATION
Certificate of Completion
EXPIRY DATE
2020-09-10
Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma has undergone significant evolution over the last decade with the advent of rituximab. Since then, a new class of targeted therapies has been developed which offers the possibility of a paradigm shift in this disease, with greater effectiveness in prolongation of progression-free survival compared to standard therapies.
Faculty
Chan Yoon Cheah
MBBS, FRACP, FRCPA, DMedSc
Clinical Senior Lecturer, University of Western Australia
Consultant Haematologist,
Sir Charles Gairdner Hospital, Perth, WA
Professor Maher Gandhi
MBChB, PhD, FRCP, FRACP, FRCPath,
LF Chair in Blood Cancer Research,
The University of Queensland Diamantina Institute,
Haematology Specialist,
Princess Alexandra Hospital, Brisbane, QLD
Accreditation
#
of credits: 1.5
Duration: 1.5 hrs
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1.5 hrs
Duration
Specialist
Profession
1.5
# of credits
Learning Objectives
Certificate of Completion
ACCREDITATION
Expired
Learning Category
General
Topic
0
Price
2020-09-10
Expiry Date
AUS
Region/Language
Course Description
Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma has undergone significant evolution over the last decade with the advent of rituximab. Since then, a new class of targeted therapies has been developed which offers the possibility of a paradigm shift in this disease, with greater effectiveness in prolongation of progression-free survival compared to standard therapies.
Faculty
Chan Yoon Cheah
MBBS, FRACP, FRCPA, DMedSc
Clinical Senior Lecturer, University of Western Australia
Consultant Haematologist,
Sir Charles Gairdner Hospital, Perth, WA
Professor Maher Gandhi
MBChB, PhD, FRCP, FRACP, FRCPath,
LF Chair in Blood Cancer Research,
The University of Queensland Diamantina Institute,
Haematology Specialist,
Princess Alexandra Hospital, Brisbane, QLD
Accreditation
This interactive online learning activity is valued at 1.5 Hour(s) of continuing education.
Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD).
1.5 hrs
Duration
0
Price
1.5
# of credits
